SUPPLEMENTARY MATERIAL

Supplementary Appendix:

Derivation of Sanz Equation:

Emax is maximal systolic ventricular elastance.

Equartion 1: Emax = ESP / (ESV - Vo)

Vo is not well characterized in human, particularly in the right ventricle, therefore Emax can be simplified as:

Equation 2: Emax = ESP/ESV

ESP (end-systolic pressure) can be approximated by using mean arterial pressure. For the right ventricle, equation 2 becomes:

Equation 3: Emax = mPAP/ESV

mPAP is mean pulmonary artery pressure.

Ea (arterial afterload) can be represented as the slope of arterial ESP versus stroke volume (SV) relationship in the volume-pressure loop and can be calculated as:

Equation 4: Ea = ESP/SV

Equation 4 becomes equation 5 when pulmonary capillary wedge pressure (PCWP) is not negligible and thus can become:


Equation 5: (mPAP – PCWP)/SV

Sanz defined ventriculo-arterial coupling as the Ea/Emax ratio derived from equations 3 and 5. They simplified the equation by disregarding the effect of PCWP in arterial load calculations and further simplified the equation to:

Equation 6:


Ea/Emax = ESV/SV

SUPPLEMENTAL FIGURE LEGENDS




Supplemental Figure 1: Right ventricular analysis of three-dimensional echocardiographic


images using the TomTec software.



Supplemental Figure 2: Discriminating ability of the Cox model. Figure A, B, C, and D show that the Areas under the ROC curves (AUC) for SV/ESV were 0.73, 0.75, 0.77, and 0.81 respectively for predicting adverse clinical event at 6, 12,18, and 24 months.



Supplemental Figure 3: Kaplan Meier curve in sub-analysis of idiopathic pulmonary arterial hypertension (IPAH) patients demonstrates that SV/ESV is a good ratio of adverse clinical events.



Supplemental Figure 4: Discriminating ability of the Cox model in sub-analysis of idiopathic pulmonary arterial hypertension (IPAH) patients. Figure A, B, C, and D show that the Areas under the ROC curves (AUC) for SV/ESV were 0.94, 0.83, 0.80, and 0.84 respectively for predicting adverse clinical event at 6, 12,18, and 24 months.

VIDEO LEGENDS:

Video 1: Three-dimensional echocardiography of the right ventricle in pediatric pulmonary hypertension patient.